SPECIAL FEATURE - Artificial Intelligence in Drug Discovery, Development & Delivery
Contributor Cindy H. Dubin speaks with leading drug makers, device manufacturers, and contract organizations who dispel the myths around AI and Machine Learning in the pharma industry and share how they are using AI to streamline clinical trials, automate lab tests, optimize resource allocation, enhance development timelines, and improve patient-friendly dosage forms.
FORMULATION FORUM - Solid Oral Dosages: Controlled Release of Drugs
Shaukat Ali, PhD, and Jim Huang, PhD, review a few examples of controlled release excipients and their attributes from monolithic matrix tablets and polymeric coated tablets.
LEADERSHIP PANEL - Trends to Watch for in 2026
Contributor Cindy H. Dubin interviews life science leaders to discuss the role of AI in drug repurposing, the future of personalized medicine, the importance of sustainability, and how to keep pace with innovation amid real-time FDA reviews.
PREFILLABLE SYRINGE SYSTEM - Beyond Components: Designing Prefillable Syringe Systems to Streamline Success
Katie Falcone says prefillable syringes for biologics and vaccines can no longer be assembled as a set of parts; they must be treated as engineered systems with data, supply, and regulatory strategies built in from the start.
CONTROLLED RELEASE - Challenges in Consistent & Predictable Delivery of Drugs Using Oral Controlled Release Technologies
True Rogers, RPh, PhD, Matthias Knarr, PhD, and Mark Dreibelbis, PhD, say excipient selection is a key consideration within the QbD framework, particularly for CR technologies. Excipients must be chosen carefully to ensure they deliver the needed processability, quality, stability, and performance during and following the manufacture of dosage forms.
EXECUTIVE INTERVIEW - Incannex Healthcare: Pioneering the Future of Cannabinoid & Psychedelic Therapies
Joel Latham, CEO of Incannex Healthcare, shares how the company navigates complex global regulatory pathways, building strategic collaborations, and forging a path toward commercial success.
CELL & GENE THERAPY - What the Industry Can Learn From Baby KJ About Optimizing CRISPR Development
Venkata Indurthi, PhD, believes the success of Baby KJ provides a model that could be replicated many times over to treat people with ultra-rare genetic diseases.
PLATFORM TECHNOLOGY - How PolyPid’s PLEX Unlocks the Potential of Local & Prolonged Release
Dikla Czaczkes Akselbrad asks what if, instead of relying on systemic delivery, a platform could be created that anchors drugs directly at the site of need and controls its release over weeks or months?
MAB FORMULATION & FILL-FINISH - Obstacles in Monoclonal Antibody Formulation & Fill-Finish
Nandkumar Deorkar, PhD, explores some of the key challenges in mAb formulation and fill-finish, offering practical insights to help developers navigate complexity and ensure success.
EXECUTIVE INTERVIEW - CERo Therapeutics: A Novel Approach to Treating Cancer
Chris Ehrlich, CEO of CERo Therapeutics, discusses the company’s science, clinical program, the treatment landscape, and more.
MRNA THERAPEUTICS - Strategies for Enhanced Stability, Targeted Delivery & Safe Translation
Carsten Rudolph, PhD, explores many challenges and the solutions offered by novel technology platforms, providing insight into the evolving landscape of mRNA drug development and its potential as a future transformative modality.
2026 COMPANY PROFILES & CAPABILITIES
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
PURIFICATION STRATEGIES - Purification at Scale: Overcoming Chromatography Challenges for Advanced Modalities
William Sanders, PhD, explores the real-world challenges of scaling chromatography and highlights how contract development and manufacturing organizations (CDMOs) can help partners overcome them.
DRUG DEVELOPMENT - Common CMC Pitfalls in Orphan Drug Development
Hibreniguss Terefe, PhD, says although the unique challenges of orphan drug development are amplified by compressed timelines and limited patient populations, common pitfalls also serve as cautionary tales for other areas of drug development.
3D PRINTING - The Future of 3D Printing in Pharma: Aprecia’s Vision for Transformative Medicine
Kyle Smith, MBA, explains how his company, a pioneer in pharmaceutical 3D printing, has a vision for distributed, patient-centric manufacturing that could re-shape the future of medicine.
EXPERT CONTENT & RESOURCES
Whether you're a researcher, a pharmaceutical professional, or simply interested in the latest advancements in drug development and delivery technology, you'll find a wealth of insightful expertise and current resources here.
How Can a Stage-Based Program to Determine HME Applicability Benefit Your API?
Low bioavailability due to poor API solubility is one of the major challenges to be overcome when developing oral dosage form drug products. An effective way of addressing this problem is to transform low solubility APIs into amorphous solid dispersions (ASDs) and can often be achieved via hot melt extrusion (HME).
2026 Drug Development Outlook: What Industry Insiders Are Saying
In this new interview, veteran pharma journalist Cindy Dubin reveals the real shifts leaders are betting on for 2026.
Antibody Validation: The Hidden Key to Reproducible Drug Discovery
As research grows more complex and data-driven, rigorous antibody validation is increasingly recognized as a critical requirement for ensuring data integrity and improving the predictive power of drug discovery pipelines.
Klotho Neurosciences: Focused on Neurodegenerative & Age-Related Disorders
Dr. Joseph Sinkule, CEO of Klotho Neurosciences, discusses the company, its therapies, the human Klotho gene, and longevity.
Operational Excellence at Scale: Why Integrated Manufacturing is the Future Biopharmaceutical Standard
Pierre Catignol explains how the conventional model creates friction when the industry needs fluidity, and integrated manufacturing answers that call by converting logistical complexity into a reliable operating rhythm that clients trust.
Have expert content to share? Contact us
EXCLUSIVE WHITEPAPERS
WHITE PAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations
This white paper explores the evolution of intradermal delivery methods, comparing historic methods of delivery such as the Mantoux technique with modern innovations such as the Terumo Immucise™ Intradermal Injection System.
WHITE PAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers
There are three key factors that need to be controlled when designing a drug product for solubility enhancement: the polymeric carrier; the manufacturing process; and the match to the desired API. By controlling these three factors bioavailability, drug release profile and manufacturability of your final drug product can be controlled.
WHITEPAPER - Drug Delivery – Recent Trends, Enabling Technologies, In-Vitro-In-Vivo Predictions & Personalized Medicine
Enabling technologies such as Nanotechnology, Amorphous Solid Dispersions, Self-emulsifying/nanoemulsifying drug delivery systems (SEDDS/SNEDDS) or Lipid Nano Particles (LNPs) for oral delivery are key elements for the development of complex and difficult to develop small molecules.
WHITEPAPER - 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing
Targeted at researchers, toxicologists and formulation scientists in the clinical and dermatological fields, the white paper provides essential insights into how advanced in vitro skin and mucosal tissue systems are reshaping research and development practices.
WHITEPAPER - OXYCAPT™: Multilayer Plastic Vial: An Optimal Primary Container for Drug Products Transported With Dry Ice
OXYCAPT™ vial is the multilayer primary container with the distinctive structure that includes the gas barrier layer in the middle layer. They offer optimal features for the transport and storage of advanced therapeutics, such as cell and gene therapy products.
EXCLUSIVE WEBINARS
ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules
In this talk we illustrate several case studies demonstrating how a fundamental understanding of molecular properties combined with a strategic vision for drug product design can lead to effective and advanceable formulations for even the most challenging drug products.
WEBINAR - Vytal: The RTU Snap-Fit System for Container Closure Solutions – Setting the Standard for the Future
In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell-based therapies, which now represent some of the most successful pharmaceutical products globally.
WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing
Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..
WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development
Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….
WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations
In this video, the Lubrizol team together with the IMCD US team takes you through formulation aspects of Carbopol® polymers as well as the results of a case study on an Acetaminophen oral suspension formulation.
MARKET NEWS & TRENDS
Calla Lily Clinical Care & Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform
Calla Lily Clinical Care and Merck have entered a strategic collaboration to support the continued development of Callavid®, a novel platform for intravaginal drug delivery.…
Eliquis Sales to Fall as European Patent Expiry Nears
Global sales of Bristol Myers Squibb’s (BMS) and Pfizer’s drug Eliquis (apixaban) are projected to decline by 15.2% in 2026 due to the loss of…
MIMETAS & Partners Launch World’s First Microphysiological Systems Industry Alliance
Today marks an important step for the global microphysiological systems (MPS) field with the launch of IAMPS – the Industry Alliance for Microphysiological Systems –…
Evogene Announces Expanded Collaboration With Google Cloud to Integrate AI Agents Into ChemPass AI
Evogene Ltd. recently announced an expanded phase of its collaboration with Google Cloud. Under this new phase, the collaboration will focus on developing and integrating…
Synthace Collaborates With Charles River to Offer Global Pharma Industry More Robust, Faster & Cost-Effective Assays
Synthace recently announced a collaboration with Charles River Laboratories International, Inc. Under the collaboration, Charles River will give its clients access to Synthace’s transformative approach to…
SPT Labtech & BellBrook Labs Introduce High-Throughput Screening Platform for Cancer Research
SPT Labtech and BellBrook Labs recently announced a collaboration to advance cancer research. Together, the companies have developed a miniaturized, high-throughput screening platform for the…
Sobi Completes Acquisition of Arthrosi Therapeutics, Strengthening Pipeline Potential Treatment of Gout
Swedish Orphan Biovitrum AB (publ) Sobi and Arthrosi Therapeutics, Inc. recently announced the completion of the acquisition of Arthrosi by Sobi. Upon completion of the…
Evinova & Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development With Artificial Intelligence
Evinova recently announced Bristol Myers Squibb has signed an agreement to optimize clinical trials with Evinova’s AI-native clinical development platform. Under the terms of the…
NeoVac Announces Positive Results Demonstrating Superior Safety Profile of Next-Generation mRNA-LNP Vaccine Platform
NeoVac recently announced positive results from first-in-human Phase I/II clinical study of NeomiVac, its investigational mRNA-LNP COVID-19 vaccine candidate. The clinical findings, now publicly available as…
SynGenSys Introduces Liver.SET Synthetic Promoter Library for Liver-Specific Gene Expression for In Vivo Gene Therapies
SynGenSys recently announced the launch of its Liver.SET library of liver-specific synthetic promoters. Developed using SyngenSys’ proprietary informatics and computational design platform, the Liver.SET library…
Evogene & Shanghai Lishan Biopharmaceuticals Announce Exclusive Licensing Agreement for a Microbiome-Based Therapeutic for Renal & Lung Cancer
Evogene Ltd. and Shanghai Lishan Biopharmaceuticals Co., Ltd. recently announced that Biomica Ltd., Evogene’s subsidiary, and Lishan Biotech entered into an exclusive worldwide licensing agreement for…
Coherus Oncology Announces Clinical Supply Agreement to Evaluate Tagmokitug in Combination With Pasritamig
Coherus Oncology, Inc. recently announced a clinical supply agreement with Johnson & Johnson to evaluate tagmokitug (CHS-114), Coherus Oncology’s investigational anti-CCR8 cytolytic monoclonal antibody, in…
Bracco Enters Cell Therapy Manufacturing With Cell Selection & Activation Technologies
Bracco Imaging recently announced its first expansion into the cell therapy space, driven by its expertise and newly developed applications of its long-established microbubble technology. Bracco's…
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph, Inc. recently announced the first patient has been dosed in the Phase 1/2 clinical trial (NCT07300241) evaluating NEO-811, a novel investigational molecular glue degrader, in…
Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection
Quanterix Corporation recently announced it has submitted a 510(k) premarket notification to the US FDA for a multi-analyte algorithmic blood test for Alzheimer’s disease (AD).…
Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies
Cellares recently announced a collaboration with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative Medicines Accelerator (IMA) to automate manufacturing and…
Alzheon Reports Plasma Biomarker Results From Phase 3 & 2 Studies, Validating First-in-Class Mechanism of Action & Underscoring Benefits in Cognition, Function & Brain Volume Protection in Alzheimer’s Patients
Alzheon, Inc. recently announced plasma biomarker analyses from its APOLLOE4 Phase 3 and Phase 2 clinical studies of valiltramiprosate/ALZ-801. New results offer robust evidence supporting the…
Sanofi’s Venglustat Met All Primary Endpoints in Phase 3 Study of Type 3 Gaucher Disease
Positive results from the LEAP2MONO Phase 3 study (clinical study identifier: NCT05222906) demonstrated that venglustat met the primary and three out of four key secondary…
MGS Launches A.i.r. Platform, Delivering New Levels of Design Flexibility for Auto-Injectors
MGS recently announced the launch of the A.i.r. Platform, a groundbreaking customizable auto-injector platform designed to meet the diverse needs of patients, Pharmaceutical innovators and…
Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
Piramal Pharma Solutions recently announce the successful development, scale-up, and commercialization of a tablet-in-capsule drug delivery system at its drug product facilities in Pithampur and Ahmedabad,…
